CAN
SRPT icon

Claraphi Advisory Network’s Sarepta Therapeutics SRPT Stock Holding History

Claraphi Advisory Network’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-150
Closed -$15K – 1062
2020
Q1 		$15K Buy
+150
New +$17.1K 0.01% 700

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Claraphi Advisory Network's SRPT Position: Q2 2020 in Review

Claraphi Advisory Network sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 150 shares — an estimated $15K sold.

Claraphi Advisory Network first reported a position in SRPT in Q1 2020 and held it in 1 quarter. The position peaked at $15K in Q1 2020. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Claraphi Advisory Network reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Claraphi Advisory Network sold 150 Sarepta Therapeutics shares in Q2 2020, an estimated $15K.
  • Claraphi Advisory Network first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 1 quarter.
  • Claraphi Advisory Network's Sarepta Therapeutics position peaked at $15K in Q1 2020.
  • 408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Claraphi Advisory Network's 13F filing for Q2 2020, filed 14 Aug 2020.